Sanofi

Note: This is a daily stock update and the information stands true as of 20/11/26, 09:00 CET

Company Update:
The firm is reportedly in talks to acquire US-based Insmed (predominantly focussed on respiratory ailments), valued at c.$32bn market cap after its yesterday’s c.21% jump. Insmed has two marketed drugs (Brinsupri and Arikayce) and five clinical-stage pipeline candidates. The company projects combined peak sales of $14bn from Brinsupri ($7bn), Arikayce ($1bn) and its lead late-stage candidate TPIP ($6bn).

We appreciate this bold move (also the need of the hour) from the management, as they seek to solve Sanofi’s burning issue of life after the lynchpin Dupixent’s (immunology; c.40% of 9M sales) patent expiration starting 2031. It is hard to ignore Sanofi’s ex-CEO Paul Hudson’s role in this potential deal, as he was appointed on Insmed board just in October 2026. Interestingly, there is not much overlap between the addressable patient population of Dupixent and Insmed’s main drugs, so there should be no worries on cannibalization. That said, a full realisation of Insmed’s peak sales expectations requires extension of exclusivity for a couple of its candidates, and it would be naïve to ignore the sprouting potential competition from other players as well.

Overall, bold moves rarely come without risks, and it might be the right time for Sanofi’s management to take some calculated chances. More details in the upcoming latest.

Expert Opinion:
Sanofi needs to find a way top offset  (at least partially) the Dupixent issue. A deal with Ismed makes a lot sense according to Abishek and would provide substantial growth to Sanofi. But we would wait until we have more details on the reality of the deal (price paid, structuration, cash and shares mix...) before committing any capital. We have no clue what price this deal could fetch and whether other bidders could come in. We would be very surprised if Sanofi could buy this top notch asset for USD30bn only.   


For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu
Subscribe to our blog


Let’s talk
Interested in our research and want to learn more?
Alphavalue Morning Market Tip
Upgrade to Add vs reduce on improved medium term prospects.
Alphavalue Morning Market Tip
No major surprise in hypermarket strategy.
Alphavalue Morning Market Tip
Strong results, FY2027 guidance raised.